INAB
Companies
NASDAQ
In8bio Inc.
Health Care
$2.19
-$5.52 (-71.60%)
Price Chart
Overview
About INAB
in8bio, inc. (“in8bio”) is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta t cells. we are developing a broad portfolio of programs and are the first company to advance genetically modified gamma-delta t cells into the clinic.
Market Cap
$59.1M
Volume
2.2M
Avg. Volume
2.7M
P/E Ratio
-0.491
Dividend Yield
0.00%
Employees
32.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.57
Low Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
High Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, INAB shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025